PDCD1 and pancreatic neoplasm: PD-L1 is one of the main targets of immune checkpoint inhibitors and pembrolizumab, an anti PD-1 monoclonal antibody, is effective in some pancreatic cancers with DNA mismatch repair deficiencies.45